People in England and Wales will soon have access to cabotegravir, a long-lasting HIV prevention jab recommended for high-risk adults and adolescents who cannot take pills. This injectable treatment is expected to benefit up to 1,000 people annually through the NHS. The jab is a significant milestone in HIV prevention, with additional drugs like lenacapavir also on the horizon, which has been approved in the EU and US. Teljes cikk (Euronews.com)